ProCE Banner Activity

Updated Analysis of Frontline Dasatinib + Blinatumomab in Patients With Newly Diagnosed Ph+ ALL

Slideset Download
Conference Coverage
High rates of MRD negativity observed in adult patients with Ph+ ALL treated with frontline dasatinib plus blinatumomab.

Released: December 18, 2019

Expiration: December 16, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company